• Ikuro Matsuba, Tetsuo Takuma, Nobuo Hatori, Masahiko Takai, Yoshiyuki Watanabe, Nobukazu Takada, Satoru Kishi, Yoko Matsuzawa, Tetsuo Nishikawa, Tomoyuki Kunishima, Hisakazu Degawa, Masanori Nishikawa, Yoshiaki Ono, Masaaki Miyakawa, Yutaka Hatori, and Akira Kanamori.
• Kanagawa Physicians Association, Japan.
• Intern. Med. 2022 Oct 15; 61 (20): 305330623053-3062.

AbstractObjective To examine the continuation of antibody prevalence status after 12 months and background factors in antibody-positive subjects following asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods We initially determined the SARS-CoV-2 anti-nucleocapsid protein immunoglobulin G (anti-N IgG) antibody prevalence in 1,603 patients, doctors, and nurses at 65 medical institutions in Kanagawa Prefecture, Japan. We then obtained consent from 33 of the 39 subjects who tested positive and performed follow-up for 12 months. Results Follow-up for up to 12 months showed that a long-term response of the anti-N IgG antibody could be detected in 6 of the 33 participants (18.2%). The proportions with hypertension, using an angiotensin-receptor blocker, and without a drinking habit were higher among the participants with a long-term anti-N IgG antibody response for up to 12 months than among those without a long-term antibody response. Conclusions The proportion of individuals with subclinical COVID-19 who continuously had a positive result for the anti-N IgG antibody at 12 months was low.

20 keywords...

hide…